

Remarks

Claims 1-7, 10 and 11 are in the application.

Claims 1, 3, and 6 have been rejected, 35 USC 102(b) as anticipated by Yokoyama, EP 0188094. Applicants have amended Claims 1 and 3, deleting the C₁₋₆alkyl moiety from the R² substituent. Support for the amended claims is found in the Specification generally, and also including the definition of R² at page 14, lines 7-8 and in Claim 2. No new matter has been added. The rejection has been overcome by this amendment. Accordingly, Applicant requests withdrawal of the rejection of claims 1 3, and 6 under 35 U.S.C. § 102(b).

The dependent claims 2, 4-5, 7, 10 and 11 have been objected to. As they depend on Claim 1, now believed to be allowable, Applicants respectfully request that these claims are also allowable. Withdrawal of the objection is respectfully requested.

It is noted that the rejection of claims 1-7, 10 and 11 under 35 U.S.C. § 112, Second Paragraph has been withdrawn.

No further issues remain outstanding against the claims in the application. Applicant respectfully requests that a timely Notice of Allowance of claims 1-7 and 10-11.

Conclusion

The Commissioner is hereby authorized to charge any deficiency or credit any overpayments necessitated by this Amendment to Deposit Account No. 10-0750/PRD2024USPCT/AGK.

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
Phone: (732) 524-2830
Dated: July 13, 2009

Respectfully submitted,

/Hesna J. Pfeiffer/

By:

Hesna J. Pfeiffer, Reg. 22,640